“Global Biosimilar Monoclonal Antibodies market worth $6.6bn in 2025” says Visiongain Report

28 February 2020
Pharma

Visiongain has published a new report Global Biosimilar Monoclonal Antibodies Forecast 2020-2030: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars.

The lead analyst of the report commented "Over the course of the forecast period, this market will expand rapidly following patent expiries of several leading innovator products and the approval of biosimilar monoclonal antibodies on the developed markets. Biosimilar versions of new biologic therapies will drive growth in this market. However, there are several biosimilar products in the development pipeline for each of the compounds discussed in this report; competition between these products will restrict revenue generation and result in a fragmented market."

Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever